Latest database descriptions

assess the prevalence, awareness, treatment and control of high blood pressure (BP) in three French areas

In the area of public health:
(1) To produce quality data to calculate health indicators for incidence, survival and prevalence.
(2) To participate in the French network of cancer registries (FRANCIM) and to collaborate with SPF and INCa as part of the national cancer surveillance programme.
(3) To work with local stakeholders at a regional level (ARS, Regional cancer network, screening sites) and to concentrate on the local use of the generated knowledge (SROS cancer research, assessment of requirements, initial and continuous training).
(4) To assess the impact of the disease on the population scale: prevalence, survival with or without the disease.

In the area of research:
(1) To learn about the distribution of therapeutic innovations throughout the population and its impact from a health and economic standpoint
(2) To assess the heterogeneity factors in the distribution of cancer treatment developments and their impact in terms of social health inequality in primary and secondary healthcare usage.
(3) To participate in studies initiated by others by providing them with local knowledge from the registry team and data collected in Tarn.

The CKD-REIN cohort will provide a research platform to address key questions regarding a number of determinants and biomarkers associated with adverse CKD outcomes and to assess clinical practices and costs in patients selected at random from a representative sample of various types of nephrology consultations. In addition, it will meet the objectives of the starting international CKD Outcomes and Practice Patterns Study (CKDopps) designed principally to identify best treatment practices in patients with advanced CKD in several countries, including France.
The objectives of the CKD-REIN study are:
(1) to study a set of social, environmental, behavioral, clinical, and genetic factors, and their interactions in relation with the outcomes of CKD and its complications, including progression to ESRD and mortality, as well as the onset of several relevant acute and chronic clinical events : acute kidney injury, infections; cardiovascular diseases, cognitive decline, bone disease, and cancer ;
(2) to assess several new biomarkers to predict adverse outcomes of CKD and its complications;
(3) to evaluate the associations of provider practices (management of hypertension and of CKD complications such as anemia, nutritional abnormalities, and bone mineral disorder; timing of dialysis initiation and transplant wait-listing) with achievement of clinical practice guidelines, clinical outcomes (survival, ESRD, hospital admissions) and patient-reported outcomes (QoL, satisfaction).
(4) to evaluate the associations of health care organization (e.g., multidisciplinary team, care network) and clinic services (e.g., for nutrition, educational programs) with clinical and patient-reported outcomes, and achievement of clinical practice guidelines;
(5) to estimate the relative cost-effectiveness of different provider practices and clinic services.
(6) to estimate the CKD incidence and prevalence in nephrology healthcare practices in France, depending on age, sex, social status, diabetes status, and depending on the stage and type of CKD.

1 - To evaluate the incidence of cancer mortality (including lung and pleura cancers) in the ARDCO cohort based on work calendar and benign asbestos-related diseases (asbestosis, pleural plaques). 2 - Evaluation of the contribution of CT examinations, thoughts on examination periodicity. 3 - To assess the psychological impact of post-occupational medical surveillance of individuals exposed to asbestos 4 - To evaluate the role of co-exposures to other carcinogens with asbestos pollution in the risk of developing cancer 5 - To contribute to defining the populations at risk of lung cancer 6 - To contribute defining optimal methods for monitoring populations previously exposed to asbestos